Preoperative use of recombinant human erythropoietin in pediatric orthopedics: a decision model for long-term outcomes

Spine Journal

Volumn 7, Issue 3, 2007, Pages 292-300

  Vitale, Michael G ^a   Roye, Benjamin D ^b   Ruchelsman, David E ^a   Roye Jr , David P ^a  

^a The Joseph L Mailman School of Public Health ^*  (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Cost effectiveness; Erythropoietin; Pediatric orthopedics; Scoliosis; Transfusion

Indexed keywords

INTERFERON; RECOMBINANT ERYTHROPOIETIN;

ACUTE LUNG INJURY; ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; BACTERIUM CONTAMINATION; BLOOD TRANSFUSION; CALCULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DONOR; FEMALE; HEMATOCRIT; HEPATITIS C; HUMAN; IDIOPATHIC SCOLIOSIS; LENGTH OF STAY; LONG TERM CARE; MEDICAL DECISION MAKING; ORTHOPEDICS; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; WOUND INFECTION;

ADOLESCENT; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; PREOPERATIVE CARE; QUALITY-ADJUSTED LIFE YEARS; SCOLIOSIS;

EID: 34247625258     PISSN: 15299430     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spinee.2006.04.004     Document Type: Article

References (49)

1. Dodd R. Adverse consequences of blood transfusion: quantitative risk estimates. In: Nance S. (Ed). Blood supply: risks, perceptions, and prospects for the future (1994), American Association of Blood Banks, Bethesda, MD 1-24
2. Goodnough L.T., Brecher M.E., Kanter M.H., and AuBuchon J.P. Transfusion medicine. First of two parts-blood transfusion. N Engl J Med 340 (1999) 438-447
3. Holland P.V. Transfusion transmitted infectious diseases. J Fla Med Assoc 80 (1993) 33-36
4. Klein H.G. Allogenic transfusion risks in the surgical patient. Am J Surg 170 (1995) 21S-26S
5. Reitman C.A., Watters III W.C., and Sassard W.R. The Cell Saver in adult lumbar fusion surgery: a cost-benefit outcomes study. Spine 29 (2004) 1580-1583
6. Vitale M.G., Stazzone E.J., Gelijns A.C., Moskowitz A.J., and Roye Jr. D.P. The effectiveness of preoperative erythropoietin in averting allogenic blood transfusion among children undergoing scoliosis surgery. J Pediatr Orthop B 7 (1998) 203-209
7. Kleinman S., Glynn S.A., Busch M., et al. NHLBI Retrovirus Epidemiology Study (REDS). The 2003 West Nile virus United States epidemic: the America's Blood Centers experience. Transfusion 45 (2005) 469-479
8. Cowell H.R., and Swickard J.W. Autotransfusion in children's orthopaedics. J Bone Joint Surg Am 56 (1974) 908-912
9. Faris P.M., Ritter M.A., and Abels R.I. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. The American Erythropoietin Study Group. J Bone Joint Surg Am 78 (1996) 62-72
10. MacEwen G.D., Bennett E., and Guille J.T. Autologous blood transfusions in children and young adults with low body weight undergoing spinal surgery. J Pediatr Orthop 10 (1990) 750-753
11. Lemos M.J., and Healy W.L. Blood transfusion in orthopaedic operations. J Bone Joint Surg Am 78 (1996) 1260-1270
12. Roye Jr. D.P., Rothstein P., Rickert J.B., Verdisco L., and Farcy J.P. The use of preoperative erythropoietin in scoliosis surgery. Spine 17 (1992) S204-S205
13. Simpson M.B., Georgopoulos G., Orsini E., and Eilert R.E. Autologous transfusions for orthopaedic procedures at a children's hospital. J Bone Joint Surg Am 74 (1992) 652-658
14. Alexander S.R. Pediatric uses of recombinant human erythropoietin: the outlook in 1991. Am J Kidney Dis 18 (1991) 42-53
15. Pierelli L., Menichella G., Scambia G., et al. In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells. Bone Marrow Transplant 14 (1994) 23-30
16. Strauss R.G. Erythropoietin in the pathogenesis and treatment of neonatal anemia. Transfusion 35 (1995) 68-73
17. Anand N., Idio Jr. F.G., Remer S., and Hoppenfeld S. The effects of perioperative blood salvage and autologous blood donation on transfusion requirements in scoliosis surgery. J Spinal Disord 11 (1998) 532-534
18. Bailey Jr. T.E., and Mahoney O.M. The use of banked autologous blood in patients undergoing surgery for spinal deformity. J Bone Joint Surg Am 69 (1987) 329-332
19. Murray D.J., Forbes R.B., Titone M.B., and Weinstein S.L. Transfusion management in pediatric and adolescent scoliosis surgery: efficacy of autologous blood. Spine 22 (1997) 2735-2740
20. Siller T.A., Dickson J.H., and Erwin W.D. Efficacy and cost considerations of intraoperative autologous transfusion in spinal fusion for idiopathic scoliosis with predeposited blood. Spine 21 (1996) 848-852
21. Simpson M.B., Georgopoulos G., and Eilert R.E. Intraoperative blood salvage in children and young adults undergoing spinal surgery with predeposited autologous blood: efficacy and cost effectiveness. J Pediatr Orthop 13 (1993) 777-780
22. Chang H., Hall G.A., Geerts W.H., Greenwood C., McLeod R.S., and Sher G.D. Allogenic red blood cell transfusion is an independent risk factor for the development of postoperative bacterial infection. Vox Sang 78 (2000) 13-18
23. Bennett W.G., Inoue Y., Beck J.R., Wong J.B., Pauker S.G., and Davis G.L. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 127 (1997) 855-865
24. Calderone R.R., Garland D.E., Capen D.A., and Oster H. Cost of medical care for postoperative spinal infections. Orthop Clin North Am 27 (1996) 171-182
25. Birkmeyer J.D., AuBuchon J.P., Littenberg B., et al. Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. Ann Thorac Surg 57 (1994) 161-168 discussion 168-9
26. Birkmeyer J.D., Goodnough L.T., AuBuchon J.P., Noordsij P.G., and Littenberg B. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 33 (1993) 544-551
27. Coyle D., Lee K.M., Fergusson D.A., and Laupacis A. Economic analysis of erythropoietin use in orthopaedic surgery. Transfus Med 9 (1999) 21-30
28. Marchetti M., and Barosi G. Cost-effectiveness of epoetin and autologous blood donation in reducing allogenic blood transfusions in coronary artery bypass graft surgery. Transfusion 40 (2000) 673-681
29. Blumberg N. Allogenic transfusion and infection: economic and clinical implications. Semin Hematol 34 (1997) 34-40
30. Carson J.L., Altman D.G., Duff A., et al. Risk of bacterial infection associated with allogenic blood transfusion among patients undergoing hip fracture repair. Transfusion 39 (1999) 694-700
31. Triulzi D.J., Vanek K., Ryan D.H., and Blumberg N. A clinical and immunologic study of blood transfusion and postoperative bacterial infection in spinal surgery. Transfusion 32 (1992) 517-524
32. Chamberland M.E. Surveillance for bloodborne infections. Thromb Haemost 82 (1999) 494-499
33. AuBuchon J.P., Birkmeyer J.D., and Busch M.P. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 37 (1997) 45-51
34. Singbartl G. Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Investig 72 (1994) S36-S43
35. Sowade B., Sowade O., Mocks J., Franke W., and Warnke H. The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med 1 (1998) 303-314
36. Keating E.M. Current options and approaches for blood management in orthopaedic surgery. In: Zuckerman J. (Ed). Instr Course Lect (1999), American Academy of Orthopaedic Surgeons, Rosemont, IL 655-665
37. Keating E.M., Ranawat C.S., and Cats-Baril W. Assessment of postoperative vigor in patients undergoing elective total joint arthroplasty: a concise patient- and caregiver-based instrument. Orthopedics 22 (1999) s119-s128
38. Powe N.R., Griffiths R.I., Watson A.J., et al. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. J Am Soc Nephrol 4 (1994) 1455-1465
39. Moran M.M., Kroon D., Tredwell S.J., and Wadsworth L.D. The role of autologous blood transfusion in adolescents undergoing spinal surgery. Spine 20 (1995) 532-536
40. Etchason J., Petz L., Keeler E., et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 332 (1995) 719-724
41. Rollo V.J., Hozack W.J., Rothman R.H., Chao W., and Eng K.O. Prospective randomized evaluation of blood salvage techniques for primary total hip arthroplasty. J Arthroplasty 10 (1995) 532-539
42. Albert T.J., Desai D., McIntosh T., Lamb D., and Balderston R.A. Early versus late replacement of autotransfused blood in elective spinal surgery: a prospective randomized study. Spine 18 (1993) 1071-1078
43. Sauaia A., Alexander W., Moore E.E., Stevens B.R., Rosen H., and Dunn T.R. Autologous blood transfusion does not reduce postoperative infection rates in elective surgery. Am J Surg 178 (1999) 549-555
44. Clark C.E., and Shufflebarger H.L. Late-developing infection in instrumented idiopathic scoliosis. Spine 24 (1999) 1909-1912
45. Fernandez M.C., Gottlieb M., and Menitove J.E. Blood transfusion and postoperative infection in orthopedic patients. Transfusion 32 (1992) 318-322
46. Rosenblum L.S., Castro K.G., Dooley S., and Morgan M. Effect of HIV infection and tuberculosis on hospitalizations and cost of care for young adults in the United States, 1985 to 1990. Ann Intern Med 121 (1994) 786-792
47. Healy J.C., Frankforter S.A., Graves B.K., Reddy R.L., and Beck J.R. Preoperative autologous blood donation in total-hip arthroplasty: a cost-effectiveness analysis. Arch Pathol Lab Med 118 (1994) 465-470
48. Havens P.L., Cuene B.E., and Holtgrave D.R. Lifetime cost of care for children with human immunodeficiency virus infection. Pediatr Infect Dis J 16 (1997) 607-610
49. Hellinger F.J. The lifetime cost of treating a person with HIV. JAMA 270 (1993) 474-478